Ganirelix Formulation



Version **Revision Date:** SDS Number: Date of last issue: 13.09.2019 16.10.2020 22220-00016 Date of first issue: 15.10.2014 5.8

Section 1: Identification

Product name **Ganirelix Formulation**

Manufacturer or supplier's details

: Organon & Co. Company

Address 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical

Section 2: Hazard identification

GHS Classification

Reproductive toxicity : Category 1B

repeated exposure

Specific target organ toxicity - : Category 1 (Bone marrow, Liver, Adrenal gland, spleen, Ovary)

GHS label elements

Hazard pictograms

Signal word

Hazard statements H360Fd May damage fertility. Suspected of damaging the un-

born child.

H372 Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.

Precautionary statements Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe mist or vapours. P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P281 Use personal protective equipment as required.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/





Version **Revision Date:** SDS Number: Date of last issue: 13.09.2019 16.10.2020 22220-00016 Date of first issue: 15.10.2014 5.8

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Ganirelix	124904-93-4	>= 0.01 -< 0.3

Section 4: First-aid measures

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. Flush eyes with water as a precaution.

In case of eye contact Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting. If swallowed

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

May damage fertility. Suspected of damaging the unborn

child.

delayed Causes damage to organs through prolonged or repeated

exposure.

Protection of first-aiders First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media Water spray

Alcohol-resistant foam Carbon dioxide (CO2)





 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 5.8
 16.10.2020
 22220-00016
 Date of first issue: 15.10.2014

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

No hazardous combustion products are known

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

Section 7: Handling and storage

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.





 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 5.8
 16.10.2020
 22220-00016
 Date of first issue: 15.10.2014

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ganirelix	124904-93-4	TWA	0.2 μg/m3 (OEB 5)	Internal
		Wipe limit	2 μg/100 cm ²	Internal

Engineering measures: Use closed processing systems or containment technologies

to control at source (e.g., glove boxes/isolators) and to pre-

vent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems

are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the

workplace.

Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally re-

auired.

Hand protection





 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 5.8
 16.10.2020
 22220-00016
 Date of first issue: 15.10.2014

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Section 9: Physical and chemical properties

Appearance : Aqueous solution

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : 5

Melting point/freezing point : No data available

Initial boiling point and boiling

range

100 °C

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : 23 hPa (20 °C)

Relative vapour density : No data available

Relative density : 1

Solubility(ies)

Water solubility : completely miscible



Ganirelix Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 5.8
 16.10.2020
 22220-00016
 Date of first issue: 15.10.2014

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

Can react with strong oxidizing agents.

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Ganirelix:

Acute toxicity (other routes of : LD50 (Rat): 40 mg/kg

administration)

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ganirelix:

Species : Rabbit



Ganirelix Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 5.8
 16.10.2020
 22220-00016
 Date of first issue: 15.10.2014

Result : Mild eye irritation Method : Draize Test

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Ganirelix:

Test Type : Maximisation Test

Species : Guinea pig Result : negative

Chronic toxicity

Germ cell mutagenicity

Not classified based on available information.

Components:

Ganirelix:

Genotoxicity in vitro : Test Type: reverse mutation assay

Test system: Salmonella typhimurium

Result: negative

Test Type: reverse mutation assay Test system: Escherichia coli

Result: negative

Test Type: in vitro assay

Test system: Chinese hamster ovary cells

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse

Application Route: Intravenous

Result: negative

Germ cell mutagenicity -

Weight of evidence does not support classification as a germ

Assessment

cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Components:

Ganirelix:

Ganirelix Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 5.8
 16.10.2020
 22220-00016
 Date of first issue: 15.10.2014

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Subcutaneous
Duration of Single Treatment: 13 Weeks

Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility

Test Type: Fertility/early embryonic development

Species: Rat, female

Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks

Fertility: LOAEL: 10 µg/kg

Result: No effects on mating performance, Effects on fertility

Test Type: Fertility Species: Monkey

Application Route: Subcutaneous

Fertility: NOAEL: 0.02 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat, female

Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 10 µg/kg

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit, female

Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 30 µg/kg

Result: Embryo-foetal toxicity

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse

effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.

Components:

Ganirelix:

Exposure routes : Ingestion

Target Organs : Bone marrow, Liver, Adrenal gland, spleen, Ovary

Assessment : Causes damage to organs through prolonged or repeated

exposure.



Ganirelix Formulation



Version Revision Date: SDS Number: Date of last issue: 13.09.2019 5.8 16.10.2020 22220-00016 Date of first issue: 15.10.2014

Repeated dose toxicity

Components:

Ganirelix:

Species : Rat

NOAEL : 0.02 mg/kg
LOAEL : 2 mg/kg
Application Route : Subcutaneous
Exposure time : 6 Months
Target Organs : Bone marrow

Species : Mouse, female LOAEL : 0.3 mg/kg
Application Route : Subcutaneous Exposure time : 3 Months

Target Organs : Liver, Adrenal gland, spleen, Ovary

Species : Mouse, male LOAEL : 3 mg/kg
Application Route : Subcutaneous Exposure time : 3 Months

Target Organs : Liver, Adrenal gland, spleen

Species : Monkey
NOAEL : 2.5 mg/kg
Application Route : Subcutaneous
Exposure time : 6 Months

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ganirelix:

Inhalation : Symptoms: The most common side effects are:, vaginal

bleeding, Headache, Abdominal pain, Nausea, ectopic preg-

nancy, miscarriage

Section 12: Ecological information

Ecotoxicity

Components:

Ganirelix:

Ecotoxicology Assessment

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

Ganirelix Formulation



Version Revision Date: SDS Number: Date of last issue: 13.09.2019
5.8 16.10.2020 22220-00016 Date of first issue: 15.10.2014

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

NZS 5433

Not regulated as a dangerous good

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

Ganirelix Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 5.8
 16.10.2020
 22220-00016
 Date of first issue: 15.10.2014

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Further information

Sheet

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals: SADT - Self-Accelerating Decomposition Temperature: SDS - Safety Data Sheet: TCSI - Taiwan Chemical Substance Inventory: TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be



Ganirelix Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 5.8
 16.10.2020
 22220-00016
 Date of first issue: 15.10.2014

considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN